Certolizumab pegol is a pegylated humanized Fab′ fragment that binds tumor necrosis factor α. In a randomized, double-blind, placebo-controlled trial, we evaluated the efficacy of certolizumab pegol ...

Please provide your email address to receive an email when new articles are posted on . The addition of certolizumab pegol to background medication for nonradiographic axial spondyloarthritis is ...

Please provide your email address to receive an email when new articles are posted on . Patients with rheumatoid arthritis and higher rheumatoid factor demonstrated better DAS28-CRP improvement with ...

Certolizumab is a therapeutic monoclonal antibody, prescribed for Crohn's disease and rheumatoid arthritis. The risk or severity of adverse effects can be increased when Certolizumab pegol is combined ...

Review the side-effects of Certolizumab as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...

The IMprove Pregnancy in APS with Certolizumab Therapy (IMPACT) clinical trial, supported by the Lupus Foundation of America through a three-year grant, found that certolizumab pegol, a medication ...

No clinically meaningful disease worsening among women with well-controlled RA, juvenile arthritis. To better understand the real-world prescribing patterns of certolizumab, researchers collected data ...

Certolizumab pegol, in combination with methotrexate, is recommended as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to, or who cannot tolerate ...

The efficacy and safety of a new tumor necrosis factor inhibitor, certolizumab pegol, in active rheumatoid arthritis has now been assessed in three phase III, multicenter, randomized, double-blind, ...

The US Food and Drug Administration (FDA) has approved the tumor necrosis factor (TNF) inhibitor certolizumab pegol (Cimzia, UCB Pharma) for the treatment of adults with active psoriatic arthritis ...

June 8, 2012 (Berlin, Germany) — Certolizumab pegol (Cimzia, UCB Pharma), a tumor necrosis factor (TNF) inhibitor approved by the US Food and Drug Administration for the treatment of rheumatoid ...

The appraisal committee considered evidence submitted by UCB Pharma and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence.